AI unwind risk rises while cure trials keep scaling

Global active cure-related trials now total 21,268, while new cure research remains brisk (56 new Cure research signals in the last 24h). At the same time, the Wire’s finance-and-AI signals are dominated by “phase transition” stress: IMF leadership warns AI-driven growth gains can coincide with tighter financial conditions and higher yields, Temasek flags the AI-trade unwind as the markets’ biggest risk, and Arthur Hayes expects an overbuilt AI infrastructure cycle to overshoot before unwinding. Even amid macro volatility and institutional self-protection narratives around AI governance, the cure pipeline shows no comparable pause—major pharma continues investing, including AstraZeneca’s new Boston R&D site backed by $1B. The signals say the capital/AI transition may be turbulent, but they also say resources still flow toward medicine; the window is still open.